- Report
- October 2024
- 200 Pages
Global
From €3371EUR$3,750USD£2,956GBP
- Report
- May 2024
- 200 Pages
Global
From €3730EUR$4,150USD£3,271GBP
- Report
- May 2024
- 200 Pages
Global
From €3730EUR$4,150USD£3,271GBP
- Report
- August 2024
- 60 Pages
Global
From €1079EUR$1,200USD£946GBP
€1348EUR$1,500USD£1,182GBP
- Report
- July 2024
- 150 Pages
Global
From €2696EUR$3,000USD£2,365GBP
€3371EUR$3,750USD£2,956GBP
- Report
- July 2024
- 100 Pages
Global
From €2696EUR$3,000USD£2,365GBP
€3371EUR$3,750USD£2,956GBP
- Report
- July 2024
- 150 Pages
Global
From €2696EUR$3,000USD£2,365GBP
€3371EUR$3,750USD£2,956GBP
- Report
- July 2024
- 100 Pages
Global
From €2696EUR$3,000USD£2,365GBP
€3371EUR$3,750USD£2,956GBP
- Report
- January 2022
- 60 Pages
Global
From €1438EUR$1,600USD£1,261GBP
€1798EUR$2,000USD£1,577GBP
- Report
- January 2022
- 60 Pages
Global
From €1079EUR$1,200USD£946GBP
€1348EUR$1,500USD£1,182GBP
- Report
- January 2022
- 60 Pages
Global
From €1079EUR$1,200USD£946GBP
€1348EUR$1,500USD£1,182GBP
- Report
- January 2022
- 60 Pages
Global
From €1079EUR$1,200USD£946GBP
€1348EUR$1,500USD£1,182GBP
- Report
- July 2024
- 120 Pages
Global
From €4269EUR$4,750USD£3,744GBP
- Report
- July 2024
- 170 Pages
Global
From €4269EUR$4,750USD£3,744GBP
- Report
- February 2024
- 179 Pages
Global
From €4269EUR$4,750USD£3,744GBP
- Report
- February 2024
- 116 Pages
Global
From €4269EUR$4,750USD£3,744GBP
- Report
- April 2023
- 110 Pages
Global
From €4269EUR$4,750USD£3,744GBP
- Report
- April 2023
- 107 Pages
Global
From €4269EUR$4,750USD£3,744GBP
- Report
- August 2022
- 115 Pages
Global
From €4269EUR$4,750USD£3,744GBP
- Report
- December 2023
- 153 Pages
Global
From €2225EUR$2,475USD£1,951GBP
€4449EUR$4,950USD£3,902GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more